NASDAQ · CV

CapsoVision, Inc.

$6.49 -$0.11 (-1.67%) 1D After hours
Session Pulse Overnight session 1 mentions on Tue No new SEC filings since Mon close its sector ranked 6/11 this week Full pulse →

Key Metrics

$329.76M
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow
Beta · 1Y 0.72
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 21
    An insider transaction hit the record.

    Form 4s are events, not verdicts — officers, directors, and 10% owners reporting their own trades. The forms post hours before the media writes them up.

    RECEIPT: SEC FORM 4, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 16
    From its Mar 24 high, the share price fell 38%.

    Peak close $8.69 on Mar 24; trough close $5.40 on Apr 16. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -38%
  • Mar 23
    The stock moved +19.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 23
  • Feb 23
    The stock moved +15.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 23

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$329.76M
Enterprise value
Shares outstanding50.0M
52-wk range$3.43 – $15.37
Avg volume · 20D236.6K
Net cash
Book value / share$0.40
IndustryElectromedical & Electrotherapeutic Apparatus
ExchangeNASDAQ
About CapsoVision, Inc.
IPO dateJul 2, 2025
Employees99

CapsoVision Inc is a commercial-stage medical technology enterprise that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio4.57
Quick ratio3.92
Debt / equity
Debt / EBITDA
Net cash
Working capital$19.14M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

Needs two fiscal years of filings

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings